NASDAQ:AGLE Aeglea BioTherapeutics (AGLE) Stock Forecast, Price & News $0.13 0.00 (0.00%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$0.12▼$0.1350-Day Range$0.12▼$0.2952-Week Range$0.11▼$1.56Volume529,403 shsAverage Volume597,962 shsMarket Capitalization$8.46 millionP/E RatioN/ADividend YieldN/APrice Target$1.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aeglea BioTherapeutics MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside1,349.0% Upside$1.88 Price TargetShort InterestHealthy0.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.47) to ($0.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 stars 3.1 Analyst's Opinion Consensus RatingAeglea BioTherapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.88, Aeglea BioTherapeutics has a forecasted upside of 1,349.0% from its current price of $0.13.Amount of Analyst CoverageAeglea BioTherapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.66% of the outstanding shares of Aeglea BioTherapeutics have been sold short.Short Interest Ratio / Days to CoverAeglea BioTherapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aeglea BioTherapeutics has recently increased by 0.49%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAeglea BioTherapeutics does not currently pay a dividend.Dividend GrowthAeglea BioTherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AGLE. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Aeglea BioTherapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AGLE on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aeglea BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeglea BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Aeglea BioTherapeutics is held by insiders.Percentage Held by Institutions78.01% of the stock of Aeglea BioTherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aeglea BioTherapeutics are expected to grow in the coming year, from ($0.47) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeglea BioTherapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeglea BioTherapeutics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeglea BioTherapeutics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aeglea BioTherapeutics (NASDAQ:AGLE) StockAeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.Read More Receive AGLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGLE Stock News HeadlinesJune 7, 2023 | americanbankingnews.comAeglea BioTherapeutics (NASDAQ:AGLE) Receives New Coverage from Analysts at StockNews.comMay 24, 2023 | americanbankingnews.comAeglea BioTherapeutics (NASDAQ:AGLE) Research Coverage Started at StockNews.comJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 15, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Aeglea BioTherapeutics (NASDAQ:AGLE)May 14, 2023 | americanbankingnews.comAeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Sees Significant Drop in Short InterestMay 14, 2023 | americanbankingnews.comBrokerages Set Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) PT at $1.25May 13, 2023 | finance.yahoo.comAeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2023 | msn.comRecap: Aeglea BioTherapeutics Q1 EarningsJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 12, 2023 | marketwatch.com10-Q: AEGLEA BIOTHERAPEUTICS, INC.May 11, 2023 | finance.yahoo.comAeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue EstimatesMay 11, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports First Quarter 2023 Financial ResultsApril 30, 2023 | americanbankingnews.comAeglea BioTherapeutics (NASDAQ:AGLE) Earns Hold Rating from Analysts at StockNews.comApril 29, 2023 | americanbankingnews.comAeglea BioTherapeutics (NASDAQ:AGLE) Coverage Initiated at StockNews.comApril 20, 2023 | americanbankingnews.comAeglea BioTherapeutics (NASDAQ:AGLE) Coverage Initiated by Analysts at StockNews.comApril 19, 2023 | americanbankingnews.comAnalysts Set Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Target Price at $1.25April 16, 2023 | americanbankingnews.comAeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Sees Large Increase in Short InterestApril 16, 2023 | americanbankingnews.comAeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to Post Q3 2023 Earnings of ($0.11) Per Share, HC Wainwright ForecastsApril 15, 2023 | americanbankingnews.comAeglea BioTherapeutics' (AGLE) Hold Rating Reiterated at JonestradingApril 14, 2023 | americanbankingnews.comAeglea BioTherapeutics (NASDAQ:AGLE) Stock Rating Lowered by Wells Fargo & CompanyApril 14, 2023 | americanbankingnews.comAeglea BioTherapeutics (NASDAQ:AGLE) Downgraded by Lifesci CapitalApril 13, 2023 | msn.comLifeSci Capital Downgrades Aeglea BioTherapeutics (AGLE)April 13, 2023 | msn.comJonesTrading Downgrades Aeglea BioTherapeutics (AGLE)April 13, 2023 | msn.comAeglea (AGLE) Plunges 26% After Rare Disorder Drug Study FailsApril 12, 2023 | msn.comWhy Are Aeglea BioTherapeutics Shares Sinking Today?April 12, 2023 | markets.businessinsider.comJonesTrading Sticks to Its Hold Rating for Aeglea Biotherapeutics (AGLE)See More Headlines AGLE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGLE Company Calendar Last Earnings5/11/2023Today6/08/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGLE CUSIPN/A CIK1636282 Webwww.aegleabio.com Phone(512) 942-2935Fax512-872-5121Employees101Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.88 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+1,349.0%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,820,000.00 Net Margins-6,678.20% Pretax Margin-6,692.96% Return on Equity-132.05% Return on Assets-96.69% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio3.51 Sales & Book Value Annual Sales$2.33 million Price / Sales3.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book0.16Miscellaneous Outstanding Shares65,390,000Free Float63,302,000Market Cap$8.46 million OptionableOptionable Beta1.74 Key ExecutivesJonathan D. AlspaughPresident, CEO, CFO, Chief Accounting OfficerScott W. RowlinsonVice President-ResearchCortney CaudillChief Product OfficerEric BradfordChief Development OfficerKelly BootheVP-Investor Relations & Corporate CommunicationsKey CompetitorsCohBarNASDAQ:CWBRCalciMedicaNASDAQ:CALCGraybug VisionNASDAQ:GRAYAdial PharmaceuticalsNASDAQ:ADILCyclacel PharmaceuticalsNASDAQ:CYCCView All CompetitorsInsiders & InstitutionsSphera Funds Management LTD.Bought 205,641 shares on 5/16/2023Ownership: 0.989%Two Sigma Investments LPSold 73,140 shares on 5/15/2023Ownership: 0.490%Carlyle Group Inc.Bought 240,500 shares on 5/5/2023Ownership: 0.368%Marcio SouzaBought 90,000 shares on 8/25/2022Total: $50,400.00 ($0.56/share)Jr. Michael Conick HanleyBought 28,200 shares on 6/8/2022Total: $20,022.00 ($0.71/share)View All Insider TransactionsView All Institutional Transactions AGLE Stock - Frequently Asked Questions Should I buy or sell Aeglea BioTherapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AGLE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGLE, but not buy additional shares or sell existing shares. View AGLE analyst ratings or view top-rated stocks. What is Aeglea BioTherapeutics' stock price forecast for 2023? 5 analysts have issued 1 year price objectives for Aeglea BioTherapeutics' shares. Their AGLE share price forecasts range from $1.00 to $3.00. On average, they predict the company's stock price to reach $1.88 in the next year. This suggests a possible upside of 1,349.0% from the stock's current price. View analysts price targets for AGLE or view top-rated stocks among Wall Street analysts. How have AGLE shares performed in 2023? Aeglea BioTherapeutics' stock was trading at $0.4499 at the start of the year. Since then, AGLE stock has decreased by 71.2% and is now trading at $0.1294. View the best growth stocks for 2023 here. When is Aeglea BioTherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our AGLE earnings forecast. How were Aeglea BioTherapeutics' earnings last quarter? Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) issued its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.17 million. Aeglea BioTherapeutics had a negative net margin of 6,678.20% and a negative trailing twelve-month return on equity of 132.05%. What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO? 3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Aeglea BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA). When did Aeglea BioTherapeutics IPO? (AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager. What is Aeglea BioTherapeutics' stock symbol? Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE." Who are Aeglea BioTherapeutics' major shareholders? Aeglea BioTherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sphera Funds Management LTD. (0.99%), Two Sigma Investments LP (0.49%), Carlyle Group Inc. (0.37%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza. View institutional ownership trends. How do I buy shares of Aeglea BioTherapeutics? Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aeglea BioTherapeutics' stock price today? One share of AGLE stock can currently be purchased for approximately $0.13. How much money does Aeglea BioTherapeutics make? Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $8.46 million and generates $2.33 million in revenue each year. The biotechnology company earns $-83,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. How many employees does Aeglea BioTherapeutics have? The company employs 101 workers across the globe. How can I contact Aeglea BioTherapeutics? Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121. This page (NASDAQ:AGLE) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeglea BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.